EMA signs off on 3 drugs re­cent­ly re­ject­ed by FDA, in­clud­ing Bio­Mar­in's new he­mo­phil­ia gene ther­a­py

The EMA’s hu­man med­i­cines com­mit­tee on Fri­day rec­om­mend­ed three new drugs for ap­proval or con­di­tion­al ap­proval, even as their US coun­ter­parts have re­ject­ed these three …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER